Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000146093 | SCV000193310 | likely benign | not specified | 2014-04-18 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001081553 | SCV001107621 | benign | D-2-hydroxyglutaric aciduria 2 | 2024-01-18 | criteria provided, single submitter | clinical testing | |
Baylor- |
RCV002467587 | SCV002764247 | uncertain significance | Enchondromatosis | criteria provided, single submitter | research | ||
Ce |
RCV000676983 | SCV004130891 | likely benign | not provided | 2024-01-01 | criteria provided, single submitter | clinical testing | IDH2: BP4, BS2 |
Prevention |
RCV003935245 | SCV004751044 | likely benign | IDH2-related disorder | 2020-11-29 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Mayo Clinic Laboratories, |
RCV000676983 | SCV000802810 | likely benign | not provided | 2016-02-26 | no assertion criteria provided | clinical testing | |
Laboratory of Diagnostic Genome Analysis, |
RCV000676983 | SCV001798438 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000676983 | SCV001963932 | likely benign | not provided | no assertion criteria provided | clinical testing |